Biotech Archives - Page 707 of 795

2 minute read

NuCana Presents Data On NUC-7738 At The European Society Of Medical Oncology Annual Meeting 2022

September 12, 10:57 AM

NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in Phase 2 PARIS,

NCNA

3 minute read

Natera Presents New Colorectal And Breast Cancer Data From The CIRCULATE-Japan Study At ESMO

By Benzinga Newsdesk

September 12, 9:29 AM

Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera,

NTRA

3 minute read

Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization In The European Union For Use As A Booster For Adults Aged 18 And Older

By Benzinga Newsdesk

September 12, 9:24 AM

Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has

NVAX

1 minute read

Synthetic Biologics Announces Phase I Study To Evaluate The Safety, Tolerability, And Efficacy Of VCN-01 In Combination With Durvalumab In Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma Of The Head And Neck Was Presented At The ESMO Congre…

By Benzinga Newsdesk

September 12, 9:22 AM

Key data and conclusions featured in the Poster Presentation include: · Safety: Treatment with VCN-01 had an acceptable safety profile when administered with durvalumab in the

SYN

1 minute read

Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer

By Vandana Singh

September 12, 9:15 AM

Clinical-stage biotech Cardiff Oncology Inc (NASDAQ:CRDF) announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC)…

CRDF

1 minute read

U.S. FDA Accepts Acadia’s Filing For Rett Syndrome Candidate Under Priority Review

By Ragothaman Srinivasan

September 12, 9:15 AM

The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.

ACAD

1 minute read

BeiGene’s Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors

By Vandana Singh

September 12, 9:08 AM

BeiGene Limited (NASDAQ:BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO)…

BAYRY

1 minute read

Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate

By Ragothaman Srinivasan

September 12, 8:49 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC).

MRSN

1 minute read

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy To Be Presented At The Rivkin Center & American Association Of Cancer Research 14th Biennial Ovarian Cancer Research Symposium

By Benzinga Newsdesk

September 12, 8:32 AM

Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose

ANIX

2 minute read

Mersana Therapeutics Announces FDA Fast Track Designation Granted To XMT-1660 For The Treatment Of Triple-Negative Breast Cancer

By Benzinga Newsdesk

September 12, 8:20 AM

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical

MRSN